2nd DNA Process Development and Manufacturing Summit

With the plasmid DNA manufacturing market set to rise to $39.3Bn by 2033, and the demand for advanced therapies continuing to surge as gene therapy reaches new heights and DNA vaccines promise to transform outbreak response, there has never been a more crucial time to revolutionize the production of high-quality DNA as a starting material and API.

The 2nd DNA Process Development and Manufacturing Summit 2025 returns as the world’s only industry-dedicated technical forum focused on optimizing process development for plasmid and cell-free DNA, adhering to regulatory requirements to streamline IND approvals for advanced therapies, and developing scalable, efficient manufacturing solutions.

Industry experts from the likes of Pfizer, Sanofi, Novartis, Beam Therapeutics, Moderna, Merck and Chroma Medicine are uniting to share innovations in plasmid design, advances off-the-shelf lysis equipment and purification techniques, and strategies to support timely, cost-efficient large-scale DNA production.

URLs:
Website: https://go.evvnt.com/2788711-0?pid=2874
Brochure: https://go.evvnt.com/2788711-3?pid=2874

Category: Conferences | Health

Prices:
Conference + 2 Workshops - Vendor - OTD: USD 5297.00,
Conference + 2 Workshops - Industry - OTD: USD 4297.00,
Conference + 2 Workshops - Discounted - OTD: USD 2599.00,
Conference + 1 Workshop - Vendor - OTD: USD 3799.00,
Conference + 1 Workshop - Discounted - OTD: USD 2599.00,
Conference + 1 Workshop - Industry - OTD: USD 3648.00,
Conference Only - Vendor - OTD: USD 3799.00,
Conference Only - Discounted - OTD: USD 2599.00,
Conference Only - Industry - OTD: USD 2999.00

Speakers: Angel Tai Manager, External Quality Assurance Operations, Sanofi, Basak Clements, Independent Expert, Brian Korniski, Senior Principal Scientist, Pfizer, Chris Lee, Associate Principal Scientist, Merck and Co, Hui Zhi, Principal Scientist, Messenger Ribonucleic Acid Process Development, Beam Therapeutics Inc., James Osborn, Senior Scientist, Preclinical Development, Merck, Jennifer Lin, Director, Preclinical MFG, Beam Therapeutics, Julen Oyarzabal, Chief Scientific Officer and Founder, SYNGOI SLU, Li Xu, Principal, RevOpsis Therapeutics, Mark Geng, Director, Global DS MS AND T DNA Lead, Moderna, Nafiseh Nafissi, Chief Technology Officer, Mediphage Bioceuticals, Nate Russart, R AND D Principle Scientist, Aldevron, Salomé de Sá Magalhães, Research Fellow, UCL, Sasha Grimm, Head of Product Management, Elegen, Suriyasri Subramanian, Senior Scientist, AstraZeneca, Swap Ghosh, Scientist, Molecular and Cell Technologies, Pfizer, Taesun Eom, Director, RNA Technologies, Chroma Medicine, Zsolt Gengeliczki, Associate Director, Analytical Project Lead, Novartis